Gibbs Wealth Management Acquires New Stake in Adaptive Biotechnologies Corporation $ADPT

Gibbs Wealth Management bought a new stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 27,592 shares of the company’s stock, valued at approximately $383,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of Adaptive Biotechnologies during the 4th quarter valued at about $28,000. EverSource Wealth Advisors LLC lifted its stake in shares of Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares during the period. KBC Group NV bought a new position in shares of Adaptive Biotechnologies in the 1st quarter worth approximately $45,000. Assetmark Inc. boosted its holdings in shares of Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after buying an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of Adaptive Biotechnologies in the fourth quarter worth approximately $51,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ADPT has been the subject of a number of research reports. Morgan Stanley upped their target price on shares of Adaptive Biotechnologies from $18.00 to $20.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. Guggenheim upped their price objective on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. JPMorgan Chase & Co. lowered their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Finally, BTIG Research reissued a “buy” rating and set a $22.00 price target on shares of Adaptive Biotechnologies in a report on Wednesday, June 17th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $20.83.

Adaptive Biotechnologies Price Performance

Shares of ADPT stock opened at $22.27 on Monday. Adaptive Biotechnologies Corporation has a one year low of $9.96 and a one year high of $23.15. The company’s fifty day moving average price is $18.49 and its 200-day moving average price is $16.42. The company has a market capitalization of $3.56 billion, a price-to-earnings ratio of -67.48 and a beta of 2.07.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. During the same quarter in the prior year, the firm posted ($0.20) EPS. Adaptive Biotechnologies’s quarterly revenue was up 35.1% compared to the same quarter last year. Equities research analysts expect that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Francis Lo sold 51,004 shares of Adaptive Biotechnologies stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $22.45, for a total transaction of $1,145,039.80. Following the sale, the insider owned 237,688 shares of the company’s stock, valued at approximately $5,336,095.60. This trade represents a 17.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Susan Bobulsky sold 11,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $18.00, for a total value of $198,000.00. Following the completion of the transaction, the insider directly owned 416,775 shares in the company, valued at approximately $7,501,950. This represents a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 813,387 shares of company stock valued at $17,049,927 over the last three months. Insiders own 5.70% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.